{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:12:18Z","timestamp":1790770338069,"version":"4.1.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"name":"Celltrion, INC"},{"name":"LYSSA LLC"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Post-exposure prophylaxis (PEP) is highly effective in preventing disease progression of rabies when used in timely and appropriate manner. The key treatment for PEP is infiltration of rabies immune globulin (RIG) into lesion site after bite exposure, besides wound care and vaccination. Unfortunately, however, RIG is expensive and its supply is limited. Currently, several anti-rabies virus monoclonal antibody (mAb) products are under development as alternatives to RIG, and two recently received regulatory approval in India. In this study, fully human mAbs that recognize different rabies virus glycoprotein conformational antigenic site (II and III) were created from peripheral blood mononuclear cells of heathy vaccinated subjects. These mAbs neutralized a diverse range of lyssavirus types. As at least two anti-rabies virus mAbs are recommended for use in human PEP to ensure broad coverage against diverse lyssaviruses and to minimize possible escape variants, two most potent mAbs, NP-19-9 and 11B6, were selected to be used as cocktail treatment. These two mAbs were broadly reactive to different types of lyssaviruses isolates, and were shown to have no interference with each other. These results suggest that NP-19-9 and 11B6 are potent candidates to be used for PEP, suggesting further studies involving clinical studies in human.<\/jats:p>","DOI":"10.1371\/journal.pone.0256779","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T13:28:20Z","timestamp":1630502900000},"page":"e0256779","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0063-628X","authenticated-orcid":true,"given":"Pan Kyeom","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Sun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Min","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Ju","family":"Keum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Joo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Joo","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Eun","family":"Maeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kye Sook","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Modupe O. V.","family":"Osinubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Franka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhusudana","family":"Shampur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Rupprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"pone.0256779.ref001","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fpubh.2017.00103","article-title":"The road to dog rabies control and elimination\u2013what keeps us from moving faster?","volume":"5","author":"AS Fahrion","year":"2017","journal-title":"Front Public Health"},{"issue":"1","key":"pone.0256779.ref002","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1186\/s12879-020-05457-x","article-title":"Towards the elimination of dog-mediated rabies: development and application of an evidence-based management tool","volume":"20","author":"K Rysava","year":"2020","journal-title":"BMC Infect Dis"},{"key":"pone.0256779.ref003","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.biologicals.2020.01.008","article-title":"Towards rabies elimination in the Asia-Pacific region: From theory to practice","volume":"64","author":"CE Rupprecht","year":"2020","journal-title":"Biologicals"},{"issue":"1","key":"pone.0256779.ref004","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/tropicalmed5010012","article-title":"Fighting Dog-Mediated Rabies in Namibia-Implementation of a Rabies Elimination Program in the Northern Communal Areas","volume":"5","author":"R Athingo","year":"2020","journal-title":"Trop Med Infect Dis"},{"issue":"9","key":"pone.0256779.ref005","doi-asserted-by":"crossref","first-page":"e0007630","DOI":"10.1371\/journal.pntd.0007630","article-title":"Healthcare demand in response to rabies elimination campaigns in Latin America","volume":"13","author":"J Yoder","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"Suppl 1","key":"pone.0256779.ref006","doi-asserted-by":"crossref","first-page":"A99","DOI":"10.1016\/j.vaccine.2018.11.072","article-title":"An overview of the immunogenicity and effectiveness of current human rabies vaccines administered by intradermal route","volume":"37","author":"M Denis","year":"2019","journal-title":"Vaccine"},{"key":"pone.0256779.ref007","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s13311-016-0452-4","article-title":"Perspectives in diagnosis and treatment of rabies viral encephalitis: insights from pathogenesis","volume":"13","author":"A Mahadevan","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"1","key":"pone.0256779.ref008","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-virology-100114-055157","article-title":"Everything you always wanted to know about rabies virus (but were afraid to ask)","volume":"2","author":"BM Davis","year":"2015","journal-title":"Ann Rev Virol"},{"key":"pone.0256779.ref009","unstructured":"World Health Organization. WHO Expert Consultation on Rabies: third report. World Health Organ Tech Rep Ser. 2018;1012:195."},{"key":"pone.0256779.ref010","first-page":"201","article-title":"Rabies vaccines: WHO position paper\u2013April 2018","volume":"93","author":"WHO\/Department of Control of Neglected Tropical Diseases","year":"2018","journal-title":"Weekly epidemiological record"},{"issue":"6","key":"pone.0256779.ref011","doi-asserted-by":"crossref","first-page":"883","DOI":"10.4103\/1673-5374.158337","article-title":"Receptor-mediated increase in rabies virus axonal transport","volume":"10","author":"S Gluska","year":"2015","journal-title":"Neural Regen Res"},{"issue":"9","key":"pone.0256779.ref012","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.4161\/hv.25431","article-title":"Feasibility of reducing rabies immunoglobulin dosage for passive immunization against rabies: results of in vitro and in vivo studies","volume":"9","author":"SN Madhusudana","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"pone.0256779.ref013","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/21645515.2015.1085142","article-title":"Local infiltration of rabies immunoglobulins without systemic intramuscular administration: an alternative cost effective approach for passive immunization against rabies","volume":"12","author":"OK Bharti","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"pone.0256779.ref014","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virol.2015.10.029","article-title":"A novel rabies vaccine based-on toll-like receptor 3 (TLR3) agonist PIKA adjuvant exhibiting excellent safety and efficacy in animal studies","volume":"489","author":"Y Zhang","year":"2016","journal-title":"Virology"},{"issue":"6","key":"pone.0256779.ref015","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ijid.2004.02.008","article-title":"Rabies deaths in Pakistan: results of ineffective post-exposure treatment","volume":"8","author":"S Parviz","year":"2004","journal-title":"Int J Infect Dis"},{"key":"pone.0256779.ref016","unstructured":"Grifols Therapeutics Inc, HyperRAB (Rabies Immune Globulin [Human]) prescribing information. 2018;3047927 https:\/\/www.grifols.com\/documents\/10192\/89815\/ft-hyper-rab-us-en\/09f14ece-e450-48f8-9137-3ce7e0aaa8c6"},{"key":"pone.0256779.ref017","unstructured":"Sanofi Pasteur SA. Product monograph including patient medication information. IMOGAM Rabies Pasteurized 2015. http:\/\/products.sanofi.ca\/en\/imogam-rabies-pasteurized.pdf"},{"key":"pone.0256779.ref018","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-1759(99)00223-9","article-title":"The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure","volume":"235","author":"JM Champion","year":"2000","journal-title":"J Immunol Methods"},{"issue":"50","key":"pone.0256779.ref019","doi-asserted-by":"crossref","first-page":"7315","DOI":"10.1016\/j.vaccine.2012.09.027","article-title":"Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults","volume":"30","author":"N Gogtay","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"pone.0256779.ref020","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/cid\/cix791","article-title":"Comparison of a novel human rabies monoclonal antibody to human rabies immunoglobulin for post-exposure prophylaxis: a phase 2\/3 randomized, Single-Blind, Noninferiority, Controlled Study","volume":"66","author":"NJ Gogtay","year":"2018","journal-title":"Clinical Infectious Diseases"},{"key":"pone.0256779.ref021","doi-asserted-by":"crossref","first-page":"ciaa779","DOI":"10.1093\/cid\/ciaa779","article-title":"Phase 3, Randomised, Open-Label, Non-inferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG)","author":"K Kansagra","year":"2020","journal-title":"Clin Infect Dis"},{"key":"pone.0256779.ref022","volume-title":"Phage Display: A Laboratory Manual","author":"CF Barbas","year":"2001"},{"issue":"1\u20132","key":"pone.0256779.ref023","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jim.2007.09.017","article-title":"Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning","volume":"329","author":"T Tiller","year":"2008","journal-title":"J Immunol Methods"},{"key":"pone.0256779.ref024","doi-asserted-by":"crossref","first-page":"9893","DOI":"10.1038\/s41598-020-66754-8","article-title":"Preparation and qualification of internal rabies reference standards for use in the rabies rapid fluorescent focus inhibition","volume":"10","author":"Tatyana M. Timiryasova","year":"2020","journal-title":"Scientific Reports"},{"key":"pone.0256779.ref025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/B978-0-12-801919-1.00018-X","volume":"2","author":"F Cliquet","year":"2015","journal-title":"Current Laboratory Techniques in Rabies Diagnosis, Research and Prevention"},{"key":"pone.0256779.ref026","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1128\/JVI.79.8.4672-4678.2005","article-title":"Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis","volume":"79","author":"WE Marissen","year":"2005","journal-title":"J Virol"},{"key":"pone.0256779.ref027","unstructured":"Applied Biosystems. DNA sequencing by capillary electrophoresis. 2009. http:\/\/tools.thermofisher.com\/content\/sfs\/manuals\/cms_041003.pdf"},{"issue":"10","key":"pone.0256779.ref028","doi-asserted-by":"crossref","first-page":"e0186380","DOI":"10.1371\/journal.pone.0186380","article-title":"Development and characterization of novel chimeric monoclonal antibodies for broad spectrum neutralization of rabies virus","volume":"12","author":"PK Kim","year":"2017","journal-title":"PLoS ONE"},{"key":"pone.0256779.ref029","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1146\/annurev.med.58.061705.145053","article-title":"A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis","volume":"58","author":"J de Kruif","year":"2007","journal-title":"Annual Review of Medicine"},{"key":"pone.0256779.ref030","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1126\/science.1135710","article-title":"Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G","volume":"315","author":"S Roche","year":"2007","journal-title":"Science"},{"key":"pone.0256779.ref031","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1016\/j.vaccine.2019.04.024","article-title":"Overview of rabies post-exposure prophylaxis access, procurement and distribution in selected countries in Asia and Africa, 2017\u20132018","volume":"37","author":"N. Sreenivasan","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"pone.0256779.ref032","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3947\/ic.2014.46.1.13","article-title":"Rabies Post-Exposure Prophylaxis of Overseas Travelers in the International Travel Clinic of the National Medical Center from 2006 to 2012, Korea","volume":"46","author":"Jong Hyun Park","year":"2014","journal-title":"Infect Chemother"},{"key":"pone.0256779.ref033","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/v6020909","article-title":"Recent Observations on Australian Bat Lyssavirus Tropism and Viral Entry","volume":"6","author":"Dawn L. Weir","year":"2014","journal-title":"Viruses"},{"key":"pone.0256779.ref034","unstructured":"Virus Taxonomy: 2012 release. Online: http:\/\/www.ictvonline.org\/virusTaxonomy.asp."},{"issue":"10","key":"pone.0256779.ref035","doi-asserted-by":"crossref","first-page":"e0141312","DOI":"10.1371\/journal.pone.0141312","article-title":"An Anti-Influenza Virus Antibody Inhibits Viral Infection by Reducing Nucleus Entry of Influenza Nucleoprotein","volume":"10","author":"Aerin Yoon","year":"2015","journal-title":"PloS ONE"},{"key":"pone.0256779.ref036","doi-asserted-by":"crossref","first-page":"7708","DOI":"10.1038\/ncomms8708","article-title":"A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus","volume":"6","author":"Y Wu","year":"2015","journal-title":"Nature Communications"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0256779","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T13:29:07Z","timestamp":1630502947000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0256779"}},"subtitle":[],"editor":[{"given":"Wanda","family":"Markotter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0256779","relation":{"has-review":[{"id-type":"doi","id":"10.32388\/N9A4OV","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]}}}